Please login to the form below

Not currently logged in
Email:
Password:

stem cell therapy

This page shows the latest stem cell therapy news and features for those working in and with pharma, biotech and healthcare.

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Takeda’ s Alofisel becomes Europe’ s first allogeneic stem cell therapy. ... Dr Asit Parikh, head of gastroenterology therapeutic area unit at Takeda, said: “Today’s marketing authorisation, the first for an allogeneic stem cell therapy,

Latest news

  • Chiesi's ultra-rare genetic disorder therapy wins European backing Chiesi's ultra-rare genetic disorder therapy wins European backing

    Chiesi's ultra-rare genetic disorder therapy wins European backing. Lamzede is set to become the first approved therapy for Alpha-Mannosidosis. ... It’s the second most advanced product from Chiesi’s rare disease unit after its LSCD therapy Holoclar

  • Transforming access in rare diseases Transforming access in rare diseases

    In Duchenne muscular dystrophy (DMD), for example, treatments from gene therapy to stem cell transplantation are all on the horizon, and all will need to be assessed by country healthcare systems

  • Celixir cleared to start trial of stem cell therapy for heart failure Celixir cleared to start trial of stem cell therapy for heart failure

    Celixir cleared to start trial of stem cell therapy for heart failure. ... Previous trial demonstrated patients achieving 100% MACE free survival. UK biotech Celixir has been given a green light to start a phase IIb trial of HeartCel - its stem

  • Takeda offers €520m for stem cell firm TiGenix Takeda offers €520m for stem cell firm TiGenix

    Takeda has launched a takeover bid for Belgian biotech TiGenix, which has completed late-stage testing of a stem cell therapy for Crohn’s disease-related complications. ... Takeda’s bid comes shortly after TiGenix’CX-601 (darvadstrocel), an

  • CHMP backs Europe’s first allogeneic stem cell therapy CHMP backs Europe’s first allogeneic stem cell therapy

    CHMP backs Europe’ s first allogeneic stem cell therapy. Takeda has ex-US rights to the Crohn's disease treatment from biotech TiGenix. ... Belgian biotech TiGenix and partner Takeda have had their stem cell therapy for perianal fistulas in Crohn’s

More from news
Approximately 3 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... A few days later Takeda announced it was paying $628m (82% share price premium) to buy Belgian company TiGenix NV and its lead asset Cx601 (darvadstrocel),

  • Pharma deals continue to slide Pharma deals continue to slide

    This referred to the CAR-T therapy, Kymriah, from Novartis for treating a form of acute lymphoblastic leukaemia in children and young adults. ... 425 (upfront 80). Calimmune (US). CSL (AU). Company acquisition. Preclinical haematopoietic stem cell

  • Cell and gene therapies: on course for commercial success? Cell and gene therapies: on course for commercial success?

    Mock assessment of a CAR-T therapy. The hypothetical CAR-T therapy was tested in two different profiles: as a bridge to haematopoietic stem cell transplantation or as a curative therapy. ... If so, how much of the per-patient price could the cell therapy

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Stem cell therapy for HF is currently being led by the likes of Bioheart (recently renamed US Stem Cell), which has muscle stem cell therapy candidate Myocell in a phase III ... trial; Mesoblast/Teva with allogenic mesenchymal stem cell therapy Neofuse;

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    225. Athersys / Chugai. Licence and collaboration Japan. Phase 2 stem cell therapy for treatment of ischaemic stroke.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Dr Jay Stout moves from Merck to SanBio Dr Jay Stout moves from Merck to SanBio

    In this role, he is responsible for all production-related operations, including clinical cell preparation, final quality assurance and process development. ... He is perhaps the individual with the greatest experience in the world in manufacturing

  • Plasticell names Aaron Chuang as chief scientific officer Plasticell names Aaron Chuang as chief scientific officer

    Chuang was an industrial advisor on high profile stem cell initiatives including UK Stem Cell Initiative, UK Cell Therapy Catapult and the California Institute of Regenerative Medicine. ... He was also prominent in establishing GSK's alliance with the

  • ReNeuron makes shifts and additions to senior team ReNeuron makes shifts and additions to senior team

    UK-based stem cell therapy company ReNeuron has announced a number of board and senior management changes. ... Dr Randolph Corteling has been promoted to head of research from his current role of head of cell biology after joining in 2007.

  • ReNeuron appoints new CEO ReNeuron appoints new CEO

    ReNeuron appoints new CEO. Olav Hellebø joins from Clavis Pharma. UK-based stem cell therapy company ReNeuron Group has appointed Olav Hellebø as its new CEO with immediate effect. ... ReNeuron's stem cell therapy candidates, will be the best way to

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics